Fundraising Fox

Kite Pharma

Santa Monica, US · Founded 2009 · 2 known investors

kitepharma.com ↗

Kite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.

BiotechHealthtech

Founders & leadership

RD
Roy DoumaniNamed on SEC filing
JA
Joshua A. KazamNamed on SEC filing
MR
Margo R. RobertsNamed on SEC filing
CB
Cynthia ButittaNamed on SEC filing
DB
David BondermanNamed on SEC filing
JM
Jonathan M. PeacockNamed on SEC filing
AS
Arie S. BelldegrunNamed on SEC filing
MB
Marc BetterNamed on SEC filing
FC
Farah ChampsiNamed on SEC filing
RN
Ran NussbaumNamed on SEC filing
SB
Steven B. RuchefskyNamed on SEC filing
RS
Rizwana SprouleNamed on SEC filing

Investors · 2

Alta PartnersJackson · $1M – $12M
Pontifax Venture CapitalHerzeliya · $6.3M – $128M

Reported raises · per SEC filings

Form D private placements

$50M disclosed across 1 round · 2014

▶$50MraisedMay 2014 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Roy DoumaniDirector
  • Joshua A. KazamDirector
  • Margo R. RobertsExecutive Officer
  • Cynthia ButittaExecutive Officer
  • David BondermanDirector
  • Jonathan M. PeacockDirector
  • Arie S. BelldegrunExecutive Officer, Director
  • Marc BetterExecutive Officer
  • Farah ChampsiDirector
  • Ran NussbaumDirector
  • Steven B. RuchefskyDirector
  • Rizwana SprouleExecutive Officer
  • Keith NolopExecutive Officer
Offering amount
$50M
Amount sold
$50M
First sale
Apr 2014
Incorporated
Corporation, Delaware, 2009
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Kardigan raises $254M, Kezar plans layoffs, Kite and Pregene ink $1.52B cell therapy deal | Partnologypartnology.com · Oct 2025Kite Pharma Raises $35M Series A Fundingleadsontrees.com · Sep 2025Two CARTs, Two Charts: Dissecting Returns From T-Cell Therapy M&Aforbes.com · Jan 2018Fledgling cancer vax biotech raises $15M in Series A | Fierce Biotechfiercebiotech.com · Mar 2011Kite Pharma Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors | Business Wirebusinesswire.com · Mar 2011

Frequently asked questions

What does Kite Pharma do?
Kite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Who are Kite Pharma's investors?
Kite Pharma's investors include Alta Partners, Pontifax Venture Capital.
How much funding has Kite Pharma raised?
Kite Pharma has disclosed $50M raised across 1 round.
Where is Kite Pharma headquartered?
Kite Pharma is headquartered in Santa Monica, US.